Synlogic Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdateMarkets InsiderSynlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to probiotics to develop novel, living medicines, today r… Continue reading
CBS NewsPatients regain sight with stem cell treatment in UK clinical trialCBS NewsNearly three years ago, 86-year-old Douglas Waters developed severe vision problems. He was diagnosed with severe wet age-related macular degeneration (AMD), a chronic e… Continue reading
Investorplace.com |
Analyzing CRISPR Therapeutics’ Q4 And Full-Year 2017 Results
Seeking Alpha For the fourth quarter 2017, CRISPR reported diluted earnings per share of $0.00 which beat EPS forecasts by $0.77; however, this is down from $0.40 per share in the fourth quarter of 2016. Full-year 2017 Diluted EPS was $(1.71), and improvement over … Does Crispr Therapeutics AG Deserve This Massive Rally?Investorplace.com Crispr Therapeutics AG (CRSP) Receives Consensus Recommendation of “Buy” from BrokeragesMacon Daily Headcount soars at Cambridge gene editing biotechs as trials nearBoston Business Journal StockNewsGazette –The Ledger Gazette –The Lincolnian Online –Zacks all 142 news articles » |
|
Daily chartChina is seeking to become a “cyber superpower”
The Economist (blog) The same applies to dominating it. Xi Jinping, China’s president, wants to take the same approach to technology more generally. He talks of making China a “cyber superpower”—one that, within a dozen years, will lead the world in artificial … |